<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291639</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH106-REC3-107</org_study_id>
    <nct_id>NCT03291639</nct_id>
  </id_info>
  <brief_title>Functional Plasticity of Human IL-17-producing CD8+ T Cells</brief_title>
  <official_title>Functional Plasticity of Human IL-17-producing CD8+ T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Tc17 cells (IL-17-producing CD8+ T cells) have been found to contribute to different&#xD;
      kinds of human inflammatory and malignant diseases. Previous studies indicate that Tc17 cells&#xD;
      can convert to Tc1 cells (IFN-γ-producing CD8+ T cells) in tumor bearing mice to exert&#xD;
      anti-tumor effect. Base on these results in murine models, human Tc17 may have potential in&#xD;
      developing cancer immunotherapy. However, there is limited evidence to reveal the&#xD;
      characteristics and functional plasticity of human Tc17 cells. In this proposal, we aim to&#xD;
      optimize the differentiation of Tc17 cells and then investigate whether the reprograming of&#xD;
      Tc17 to Tc1 cells can promote the anti-tumor cytotoxicity. Preliminarily, we isolated CD8+ T&#xD;
      cells from the peripheral blood mononuclear cells of healthy donors to induce Tc17&#xD;
      differentiation. Human CD8+ T cells were stimulated with anti-CD3/anti-CD28 antibodies,&#xD;
      TGF-β, IL-1β, IL-6, IL-23, IL-2, anti-IFN-γ, and anti-IL-4 antibodies. After 10 days in&#xD;
      culture, there were 4% of IL-17A+IFN-γ- and 7% of IL-17A+IFN-γ+ CD8+ T cells. However, IFN-γ+&#xD;
      CD8+ T cells still represented high percentage, although it's significantly lower than that&#xD;
      in Tc1 cells. Our preliminary study demonstrated that Tc17 cells expressed lower levels of&#xD;
      cytotoxic molecules than Tc1 cells. We will further test if the expressions of cytotoxic&#xD;
      molecules, including perforin and granzyme B, and EOMES will be enhanced by various&#xD;
      cytokines. Ultimately, we will evaluate the functional plasticity of Tc17 cells under various&#xD;
      cytokine stimulation. Collectively, success of this project will establish more insight for&#xD;
      human Tc17 cells and provide the information for future developing human CD8+ T cell-mediate&#xD;
      immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 25, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Functional plasticity of IL-17+ CD8 T cells</measure>
    <time_frame>culture cells for 16 days</time_frame>
    <description>To skew human IL-17+ CD8 T cells and add specific cytokines to convert IL-17 CD8 T cells to IFN-gamma CD8 T cells</description>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>IL-17+ CD8 T Cells in Cancer Patients</condition>
  <eligibility>
    <study_pop>
      <textblock>
        10 healthy donors and 20 cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cancer patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

